Last updated on August 2019

IRX-2 Regimen and Durvalumab for Incurable H&N Squamous Cell Carcinoma

Brief description of study

The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.

Detailed Study Description

Study Population:

Patients with histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of oral cavity, oropharynx, paranasal sinuses, hypopharynx, or larynx that is not amenable to local therapy with curative intent. Squamous cell carcinoma of unknown primary in cervical lymph node can be included only if p16 status is positive.

Clinical Study Identifier: NCT03381183

Find a site near you

Start Over